Important Information for Investors of Pacira BioSciences, Inc. (PCRX): Rosen Law Firm Announces Class Action Lawsuit and Lead Plaintiff Deadline
On February 24, 2025, Rosen Law Firm, a leading investor rights law firm, announced that it has filed a class action lawsuit on behalf of all persons or entities that purchased securities of Pacira BioSciences, Inc. (PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges that the Company issued materially false and misleading statements to the investing public.
Background:
According to the complaint, during the Class Period, Pacira BioSciences, Inc. made false and/or misleading statements and/or failed to disclose that:
- The Company’s EXPAREL product, a non-opioid local anesthetic, was experiencing lower than expected sales;
- The Company’s sales and marketing efforts for EXPAREL were inadequate;
- The Company’s financial statements were not accurate;
Impact on Individual Investors:
If you purchased Pacira BioSciences securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline for this case is March 14, 2025. To participate in this class action lawsuit, you must have purchased Pacira BioSciences securities during the Class Period and have suffered a loss as a result. If you meet these requirements, please contact Rosen Law Firm as soon as possible to discuss your potential recovery.
Impact on the World:
The filing of this class action lawsuit against Pacira BioSciences, Inc. is significant because it raises important questions about the accuracy of the Company’s financial statements and its sales and marketing efforts. This case also highlights the importance of transparency and accuracy in the reporting of financial information, particularly for companies in the healthcare sector. As the healthcare industry continues to evolve, it is crucial that investors have access to reliable and accurate information to make informed decisions.
Conclusion:
The filing of this class action lawsuit against Pacira BioSciences, Inc. is an important step in holding the Company accountable for any misrepresentations made during the Class Period. If you believe you may be affected by this case, it is important to act quickly and contact Rosen Law Firm as soon as possible to discuss your potential recovery. This case also serves as a reminder of the importance of transparency and accuracy in financial reporting, particularly in the healthcare sector.
If you have any further questions or need additional information, please do not hesitate to contact us.
